🚀 VC round data is live in beta, check it out!
Hyperfine Valuation Multiples
Discover revenue and EBITDA valuation multiples for Hyperfine and similar public comparables like Edap TMS, Aroa Biosurgery, Onyx Healthcare, CROSSJECT and more.
Hyperfine Overview
About Hyperfine
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
Founded
2021
HQ
Employees
111
Website
Financials (LTM)
EV
$94M
Hyperfine Financials
Hyperfine reported last 12-month revenue of $15M and negative EBITDA of ($34M).
In the same LTM period, Hyperfine generated $8M in gross profit, ($34M) in EBITDA losses, and had net loss of ($35M).
Revenue (LTM)
Hyperfine P&L
In the most recent fiscal year, Hyperfine reported revenue of $14M and EBITDA of ($35M).
Hyperfine expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $15M | XXX | $14M | XXX | XXX | XXX |
| Gross Profit | $8M | XXX | $7M | XXX | XXX | XXX |
| Gross Margin | 51% | XXX | 50% | XXX | XXX | XXX |
| EBITDA | ($34M) | XXX | ($35M) | XXX | XXX | XXX |
| EBITDA Margin | (217%) | XXX | (259%) | XXX | XXX | XXX |
| EBIT Margin | (231%) | XXX | (273%) | XXX | XXX | XXX |
| Net Profit | ($35M) | XXX | ($36M) | XXX | XXX | XXX |
| Net Margin | (226%) | XXX | (262%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Hyperfine Stock Performance
Hyperfine has current market cap of $129M, and enterprise value of $94M.
Market Cap Evolution
Hyperfine's stock price is $1.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $94M | $129M | 0.0% | XXX | XXX | XXX | $-0.36 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHyperfine Valuation Multiples
Hyperfine trades at 6.0x EV/Revenue multiple, and (2.8x) EV/EBITDA.
EV / Revenue (LTM)
Hyperfine Financial Valuation Multiples
As of April 20, 2026, Hyperfine has market cap of $129M and EV of $94M.
Equity research analysts estimate Hyperfine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hyperfine has a P/E ratio of (3.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $129M | XXX | $129M | XXX | XXX | XXX |
| EV (current) | $94M | XXX | $94M | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBITDA | (2.8x) | XXX | (2.7x) | XXX | XXX | XXX |
| EV/EBIT | (2.6x) | XXX | (2.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 12.0x | XXX | 13.9x | XXX | XXX | XXX |
| P/E | (3.7x) | XXX | (3.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Hyperfine Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Hyperfine Margins & Growth Rates
Hyperfine's revenue in the last 12 month grew by 41%.
Hyperfine's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.
Hyperfine's rule of 40 is (101%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hyperfine's rule of X is (29%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Hyperfine Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 41% | XXX | 48% | XXX | XXX | XXX |
| EBITDA Margin | (217%) | XXX | (259%) | XXX | XXX | XXX |
| EBITDA Growth | (14%) | XXX | (15%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (101%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (29%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 68% | XXX | 75% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 105% | XXX | 120% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 109% | XXX | 129% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 323% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Hyperfine Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hyperfine | XXX | XXX | XXX | XXX | XXX | XXX |
| Edap TMS | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Onyx Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| CROSSJECT | XXX | XXX | XXX | XXX | XXX | XXX |
| Treace Medical Concepts | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hyperfine M&A Activity
Hyperfine acquired XXX companies to date.
Last acquisition by Hyperfine was on XXXXXXXX, XXXXX. Hyperfine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Hyperfine
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHyperfine Investment Activity
Hyperfine invested in XXX companies to date.
Hyperfine made its latest investment on XXXXXXXX, XXXXX. Hyperfine invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Hyperfine
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Hyperfine
| When was Hyperfine founded? | Hyperfine was founded in 2021. |
| Where is Hyperfine headquartered? | Hyperfine is headquartered in United States. |
| How many employees does Hyperfine have? | As of today, Hyperfine has over 111 employees. |
| Who is the CEO of Hyperfine? | Hyperfine's CEO is Maria Sainz. |
| Is Hyperfine publicly listed? | Yes, Hyperfine is a public company listed on Nasdaq. |
| What is the stock symbol of Hyperfine? | Hyperfine trades under HYPR ticker. |
| When did Hyperfine go public? | Hyperfine went public in 2021. |
| Who are competitors of Hyperfine? | Hyperfine main competitors are Edap TMS, Aroa Biosurgery, Onyx Healthcare, CROSSJECT. |
| What is the current market cap of Hyperfine? | Hyperfine's current market cap is $129M. |
| What is the current revenue of Hyperfine? | Hyperfine's last 12 months revenue is $15M. |
| What is the current revenue growth of Hyperfine? | Hyperfine revenue growth (NTM/LTM) is 41%. |
| What is the current EV/Revenue multiple of Hyperfine? | Current revenue multiple of Hyperfine is 6.0x. |
| Is Hyperfine profitable? | No, Hyperfine is not profitable. |
| What is the current EBITDA of Hyperfine? | Hyperfine has negative EBITDA and is not profitable. |
| What is Hyperfine's EBITDA margin? | Hyperfine's last 12 months EBITDA margin is (217%). |
| What is the current EV/EBITDA multiple of Hyperfine? | Current EBITDA multiple of Hyperfine is (2.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.